# Temporal Changes in Management of Acute Coronary Syndromes

Thesis
Submitted for Partial fulfillment of Master Degree in
Cardiovascular Medicine
By

Hesham Mohamed Bahaa Eldin Mohamed Saied (M.B., B.Ch)

Supervised by

#### Prof. Dr. Soliman Ghareeb

Professor of Cardiology
Faculty of Medicine – Cairo University

#### Prof. Dr. Ahmed Magdy Kamal Eldin

Consultant of Cardiology National Heart Institute

#### Dr. Waleed Abd El-salam Ammar

Assistant Professor of Cardiology Faculty of Medicine – Cairo University

> Faculty of Medicine Cairo University 2014

### <u>ACKNOWLEDGMENT</u>

First and foremost, all the thanks to ALLAH the most beneficent and merciful.

I would like to express my deepest gratitude to **Prof. Dr.**Soliman Ghareeb, Professor of Cardiology, Faculty of Medicine,

Cairo University, for his endless guidance and patience
throughout my journey in writing this study.

I would like to express my profound thanks to **Prof. Dr.**Ahmed Magdy Professor of Cardiology, National Heart Institute, for teaching me the way of thinking and for having the seed of this work, and also for having the clear vision for making this work see the light.

I will not be grateful enough to **Dr. Waleed Abdel Salam**Ammar, Asst. professor of Cardiology, Faculty of Medicine, Cairo

University, not only for his supervision of this work, step by step

in all its stages, but also for teaching me how a mentor should be.

Last and not least, I would like thank all my Family, friends and colleagues for bearing all the trouble with me and encouraging me all through.

Dedication	
I dedicate this work to my Father the man I will always look up to till the day I die, my Mother the charm of my life, and my brother and sister for the happiness they fill my heart with.	

#### **ABSTRACT**

- ❖ <u>BACKROUND:</u> Acute Coronary Syndromes(ACS) represent a continuum of disease ranging from unstable angina, associated with reversible myocardial cell injury, to ST-segment elevation of myocardial infarction, associated with irreversible myocardial necrosis [11][2]. It represents the acute life threatening phase of coronary artery disease (3). Current knowledge regarding the characteristics, treatments and outcomes of patients diagnosed with the complete spectrum of acute coronary syndromes is limited to data derived from
- clinical trials and/or from national registries. Acute coronary syndrome patients enrolled in randomized, clinical trials are a highly selected, lower-risk subgroup. Hence, unless the trial is very large and heterogeneous, it tends to reflect an 'ideal' study set rather than the diversity of clinical practice. (4)
- ❖ *Objective:* To better delineate the change in the characteristics, treatments, and outcomes of patients with (ACS) by comparing current results with those of previous local registries that have been done in the past years.
- ❖ <u>METHODS:</u> This study was performed in the National Heart Institute CCU and Kasr Einy hospitals, including a total of 1807 patients diagnosed as having acute coronary syndrome. 606 patients were collected prospectively (group 3) and compared with 1201 patients collected retrospectively from previous national registries performed in the national Heart Institute from 2007(group 1) to 2010 (group 2). Data of all patients included: Full history taking including risk factors, full clinical examination, ECG, echocardiography management including modality of reperfusion, adjunctive medical treatment and whether

coronary angiography+/- PCI was done or not; outcome and in hospital mortality.

- ❖ RESULT: percentage of STEMI increased among those presenting with ACS. (from 59% in G1 vs. 63% in G2 reaching almost 74% in G3)P<0.001. The mean ages were 54.5 +/- 11.8 G1, 56.9 +/- 10.6 in G2, and 54.3 +/- 10.9 in G3. Significant drop in mean age occurred G2 vs. G3 (P=0.001). Gender distribution hasn't change significantly. Smoking and diabetes increased with no statistical significance.Patients with previous PCI increased significantly 5% in G1 5.6% in G2 reaching 12% in G3 (P=0.001). Coronary Angiography increased from 40 % in G1 to 52% in G3(P<0.001). PCI was done to 48.3 % of admitted patients of G3 vs. 22% in G2 (P<0.001) and 26% in G1(P<0.001). Primary PCI has increased significantly 12.36% G1(P=0.001), 13% G2(P=0.001), and almost 40% G3. Door to needle (DTN) and door to balloon (DTB) showed no statistical difference. DTN 20 +/- 8 min G1 vs 21.5 +/- 7.3 minutes (P=0.105), while DTB 102 +/- 10.9 min G1 vs. 101.5 +/- 26.6 min (P=0.86). Overall complications have decreased significantly. Mortality has improved, 4.24% G1 vs. 2.5% in G3 (P=0.044)
- ❖ <u>CONCLUSION:</u> Smoking, Hypertension, and diabetes are significant risk factors, which increased over the past years. This finding necessitates the formulation of programs for primary and secondary prevention of coronary artery disease. The intervention stratigies have seen some flourishment. The percentage of PCI increased significantly, but still thombolysis is the primary reperfusion modality. That shows the need for developing our insurance system to cover a broader spectrum with more services.

#### **Keywords**

Acute coronary syndromes
Registry
Primary PCI
Temporal changes

## **CONTENTS**

List of Abbreviation	I
List of Figures	IV
List of Tables	VI
Introduction	1
Aim of the Work	3
Review of Litreature	4
Chapter I :- Pathophysiology	4
Chapter II :- Risk Factors	13
Chapter III :- Management of ACS	28
Management of STEMI	28
Management of NSTE-ACS	42
Adjunctive Medical treatment in ACS:-	46
Chapter IV: Important Registries of ACS	54
• Importance of registries in clinical practice:-	54
• Examples of Important registries and findings:-	56
Patients and Methods	63
Results	70
Discussion	86
Summary	99
Conclusion	104
Recommendations	105
Limitations of the Study	
Reference	
Arabic Summary	

## List of Abbreviation

ACS Acute Coronary Syndrome

ACC American college of cardiology

ACE Acetyl Choline Esterase

**ADP** Adenosine **D**i-**P**hosphate

AMI Acute Myocardial infarction

ATP Adenosine Tri-Phosphate

BMI Body Mass Index

BMS Bare metal Stents

**BP** Blood Pressure

CABG Coronary Artery Bypass Grafting

CARESS - AMI Combined Abciximab RE-teplase Stent Study

in Acute Myocardial Infarction

CHD Coronary Heart Disease

COURAGE Clinical Outcomes Utilizing Revascularization

and Aggressive Drug Evaluation

CPR CardioPulmonary Resuscitation

CT Computed Tomographic

CVD Cardiovascular Disease

Door-to-Balloon

Door-to-Needle

DBP Diastolic Blood Pressure

**DES** Drug Eluting Stens

**DIDO** Door In Door Out

ECG Electro-Cardio-Graphy

ED Emergency Department

EHS Euro Heart Survey

EMS Emergency Medical Service

ESC European Society of Cardiology

**FAST-MI** The French registries of Acute **ST**-elevation and

non-ST-elevation Myocardial Infarction

FMC First Medical Contact

GFR Glomerular Filtration Rate

**GP** Glycoprotein

GRACE The Global Registry of Acute Coronary Events

GUSTO-I Global Utilization of Streptokinase and TPA

(alteplase) for Occluded Coronary Arteries

HDL High-Density Lipoprotein

HF Heart Failure

HR Hazard Ratio

ICH Intracranial Hemorrhage

IMT Intima-media thickness

LBBB Left Bundle Branch Block

LDL Low-Density Lipoprotein

LOE Level Of Evidence

MI Myocardial Infarction

MMP Matrix-metalloproteinase

NCDR National Cardiovascular Data Registry

NCEP/ATP-III National Cholesterol Education Program/

**Adult Treatment Panel** 

NRMI The National Registry of Myocardial Infarction

OAT Occluded Artery Trial

**OR** Odds **R**atio

PAD Peripheral Arterial Disease

PPCI Primary Percutaneous Coronary Intervention

**RCT** Randomized Controlled Trials

**REACH** Reduction of Atherothrombosis for Continued

Health

**RR** Relative Risk

SBP Systolic Blood Pressure

SK Streptokinase

STEMI ST-Elevation Myocardial Infarction

STREAM STrategic Reperfusion Early After

**Myocardial infarction** 

TIMI Thrombolysis in Myocardial Infarction

TRANSFER-AMI Trial of Routine Angioplasty and Stenting after

Fibrinolysis to Enhance Reperfusion in Acute

**Myocardial Infarction** 

TxA2 Thromboxane A2

**UFH** Unfractionated **H**eparin

VLDL Very Low Density Lipoprotein

VO<sub>2</sub> Volume of Oxygen

# **List of Figures**

• Figure 1 Characteristics of Atherosclerotic Plaque	es
Associated with Various Presentation of Coronary Arter	ry
Disease	7
• Figure 2 Superficial Erosion of Plaques 1	2
• Figure 3 Percutaneous Coronary Angiography an	ıd
Intervention in the Treatment of Arterial Stenosis 2	29
• Figure 4 Relative Risk of In-Hospital Death with Each Additional 15-Minute Interval and Number of Death Associated with Increases in Door-to-Balloon Time at Compared with Treatment within 90 Minutes	ch hs
Eigen 5 character flow shout of notice to appear the h	
• Figure 5 shows the flow chart of patients presenting b	Ĭ
STEMI 3	54
• Figure 6 Symptom onset to FMC <sup>(179)</sup>	58
• Figure 7 Reperfusion modalities over the years (179) 5	58
• Figure 8 Reperfusion modalities across time (180)	50
• Figure 9 Trends in reperfusion for reperfusion-eligibate STEMI patients, 1990 to 2006	
• Figure 10 Door to Balloon times over the years 6	52
• Figure 11: Initial Diagnosis of study groups	71

•	Figure 12: Mean Age over the years	72
•	Figure 13 Gender distribution	72
•	Figure 14: Previous Events	75
•	Figure 15 Main presentation	75
•	Figure 16 Invasive in hospital Procedures	79
•	Figure 17 Management of STEMI	80
•	Figure 18 Medical therapy	82
•	Figure 19 In hospital Complications	84
•	Figure 20 In- hospital Mortality	85

## **List of Tables**

•	Table 1 Grades of Hypertension	3
•	Table 2 Differential Diagnosis of NSTE-ACS4	3
•	Table 3 initial diagnosis70	0
•	Table 4 Mean Age over the years	2
•	Table 5 Risk Factors	3
•	Table6 : Previous Events/Interventions	4
•	Table 7 : Symptom to admission interval in all patients presenting with ACS	
•	Table8 : Time to FMC in STEMI7	7
•	Table 9 vital signs	8
•	Table 10 showing Invasive in hospital procedures78	8
•	Table 11 showing reperfusion Strategies	9
•	Table 12 Adjunctive medical treatment8	1
•	Table 13 Inhospital Complications	3
•	Table 14 Left ventricular Ejection Fraction over years84	4
•	Table 15 in hospital mortality8	5

## **Introduction**

Acute coronary syndromes (ACS) represent the acute life threatening phase of coronary artery disease <sup>(1)</sup>. Current knowledge regarding the characteristics, treatments and outcomes of patients diagnosed with the complete spectrum of acute coronary syndromes is limited to data derived from clinical trials and/or from national registries. ACS patients enrolled in randomized, clinical trials are a highly selected, lower-risk subgroup. Hence, unless the trial is very large and heterogeneous, it tends to reflect an 'ideal' study set rather than the diversity of clinical practice. <sup>(2)</sup>

In contrast, registries and surveys have the potential to define the 'gaps' between evidence and practice as well as implementation of guidelines. (3)

Randomized trials provide robust evidence for the impact of pharmacological and interventional treatments in patients with ST-segment elevation and non–STsegment elevation acute coronary syndromes (NSTE ACS), leading to changes in practice guidelines. (4)

However, the extent and time course of changes in clinical practice are uncertain, and it is unknown whether such changes are associated with improved outcome. Previous studies have documented substantial gaps between guideline recommendations and clinical practice. Thus, there is a clinical priority to determine the extent to which evidence is applied in practice, whether this is changing over time, and whether such changes are associated with improved outcomes. (5)

Also, in the past few years a lot of non-governmental organizations helped the governmental hospitals financially to improve the outcome of the ACS patients by supplying the hospitals with Stents and other supplies which are necessary for performing Primary PCI.

This phenomenon had to be studied in order to know its effect on the outcome of patients with ACS.

So the best way to do so was to compare a registry of the present time with those of the past years, and correlate this to the outcome on the morbidity and mortality of the patients suffering from ACS.

## **Aim of the Work**

To delineate the change in the characteristics, treatments, and outcomes of patients with ACS over the years in tertiary centers.